Cargando…
A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis
BACKGROUND: Recently studies have demonstrated that the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) may participate in the development and progression of lung cancer. In this study, we hypothesized that genetic variant of this lncRNA may affect the pr...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335789/ https://www.ncbi.nlm.nih.gov/pubmed/28253859 http://dx.doi.org/10.1186/s12885-017-3151-6 |
_version_ | 1782512106189357056 |
---|---|
author | Wang, Jian-Zhong Xiang, Jing-Jun Wu, Li-Ge Bai, Yan-Sen Chen, Zhuo-Wang Yin, Xiang-Qian Wang, Qing Guo, Wen-Hao Peng, Ying Guo, Huan Xu, Ping |
author_facet | Wang, Jian-Zhong Xiang, Jing-Jun Wu, Li-Ge Bai, Yan-Sen Chen, Zhuo-Wang Yin, Xiang-Qian Wang, Qing Guo, Wen-Hao Peng, Ying Guo, Huan Xu, Ping |
author_sort | Wang, Jian-Zhong |
collection | PubMed |
description | BACKGROUND: Recently studies have demonstrated that the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) may participate in the development and progression of lung cancer. In this study, we hypothesized that genetic variant of this lncRNA may affect the prognosis of lung cancer patients. METHODS: We conducted a follow-up study for 538 patients with non–small cell lung carcinoma (NSCLC), including 140 early-staged (stage I and II) and 398 advanced staged (stage III and IV) patients. The genetic variant rs3200401 in MALAT1 was then genotyped among this population by using TaqMan assay. The association of this variant with overall survival of these patients was further analyzed. RESULTS: It was shown that among the advanced lung adenoma patients, subjects carrying rs3200401 CT and CT + TT genotypes had significantly longer median survival time (MST = 29.9, 28.9 vs. 19.3 month, Long-rank P = 0.019 and 0.024, respectively) and decreased death risks [crude HR (95% CI) = 0.65 (0.43–0.98) and 0.64 (0.44–0.95), P = 0.040 and 0.025, respectively], when compared to subjects wtih the MALAT1 rs3200401 CC genotype. However, the beneficial effect of rs3200401 was not seen among early NSCLC and advanced lung squamous cell carcinoma patients. We further tested the TCGA data, and found that a higher expression of MALAT1 was associated with metastatic of advanced lung adenocarcinoma but not with lung squamous cell carcinoma. CONCLUSIONS: The rs3200401 T allele located on the lncRNA MALAT1 was associated with a better survival for advanced lung adenocarcinoma patients, which may offer a novel prognostic biomarker for this patient subgroup. However, these results need to be validated in larger populations of lung cancer and the biological function of this variant still warrants further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3151-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5335789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53357892017-03-07 A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis Wang, Jian-Zhong Xiang, Jing-Jun Wu, Li-Ge Bai, Yan-Sen Chen, Zhuo-Wang Yin, Xiang-Qian Wang, Qing Guo, Wen-Hao Peng, Ying Guo, Huan Xu, Ping BMC Cancer Research Article BACKGROUND: Recently studies have demonstrated that the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) may participate in the development and progression of lung cancer. In this study, we hypothesized that genetic variant of this lncRNA may affect the prognosis of lung cancer patients. METHODS: We conducted a follow-up study for 538 patients with non–small cell lung carcinoma (NSCLC), including 140 early-staged (stage I and II) and 398 advanced staged (stage III and IV) patients. The genetic variant rs3200401 in MALAT1 was then genotyped among this population by using TaqMan assay. The association of this variant with overall survival of these patients was further analyzed. RESULTS: It was shown that among the advanced lung adenoma patients, subjects carrying rs3200401 CT and CT + TT genotypes had significantly longer median survival time (MST = 29.9, 28.9 vs. 19.3 month, Long-rank P = 0.019 and 0.024, respectively) and decreased death risks [crude HR (95% CI) = 0.65 (0.43–0.98) and 0.64 (0.44–0.95), P = 0.040 and 0.025, respectively], when compared to subjects wtih the MALAT1 rs3200401 CC genotype. However, the beneficial effect of rs3200401 was not seen among early NSCLC and advanced lung squamous cell carcinoma patients. We further tested the TCGA data, and found that a higher expression of MALAT1 was associated with metastatic of advanced lung adenocarcinoma but not with lung squamous cell carcinoma. CONCLUSIONS: The rs3200401 T allele located on the lncRNA MALAT1 was associated with a better survival for advanced lung adenocarcinoma patients, which may offer a novel prognostic biomarker for this patient subgroup. However, these results need to be validated in larger populations of lung cancer and the biological function of this variant still warrants further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3151-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-03 /pmc/articles/PMC5335789/ /pubmed/28253859 http://dx.doi.org/10.1186/s12885-017-3151-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Wang, Jian-Zhong Xiang, Jing-Jun Wu, Li-Ge Bai, Yan-Sen Chen, Zhuo-Wang Yin, Xiang-Qian Wang, Qing Guo, Wen-Hao Peng, Ying Guo, Huan Xu, Ping A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis |
title | A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis |
title_full | A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis |
title_fullStr | A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis |
title_full_unstemmed | A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis |
title_short | A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis |
title_sort | genetic variant in long non-coding rna malat1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335789/ https://www.ncbi.nlm.nih.gov/pubmed/28253859 http://dx.doi.org/10.1186/s12885-017-3151-6 |
work_keys_str_mv | AT wangjianzhong ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT xiangjingjun ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT wulige ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT baiyansen ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT chenzhuowang ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT yinxiangqian ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT wangqing ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT guowenhao ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT pengying ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT guohuan ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT xuping ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT wangjianzhong geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT xiangjingjun geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT wulige geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT baiyansen geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT chenzhuowang geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT yinxiangqian geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT wangqing geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT guowenhao geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT pengying geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT guohuan geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis AT xuping geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis |